CF
SPRY icon

Corebridge Financial’s ARS Pharmaceuticals SPRY Stock Holding History

Corebridge Financial’s Portfolio SPRY Stock Details SPRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-24,109
Closed -$303K – 2408
2025
Q1 		$303K Sell
24,109
-358
-1% -$4.31K ﹤0.01% 1846
2024
Q4 		$258K Sell
24,467
-1,846
-7% -$25.9K ﹤0.01% 2022
2024
Q3 		$382K Sell
26,313
-163
-0.6% -$1.94K ﹤0.01% 1876
2024
Q2 		$225K Buy
+26,476
New +$235K ﹤0.01% 2122

Other funds holding SPRY

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Corebridge Financial's SPRY Position: Q2 2025 in Review

Corebridge Financial sold out of ARS Pharmaceuticals (SPRY) in Q2 2025, closing a stake of 24,109 shares — an estimated $303K sold.

Corebridge Financial first reported a position in SPRY in Q2 2024 and held it in 4 quarters. The position peaked at $382K in Q3 2024. 187 funds tracked by Wall St. Rank hold SPRY as of Q2 2025.

  • Corebridge Financial reported no remaining ARS Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • Corebridge Financial sold 24,109 ARS Pharmaceuticals shares in Q2 2025, an estimated $303K.
  • Corebridge Financial first reported a position in ARS Pharmaceuticals in Q2 2024 and held it in 4 quarters.
  • Corebridge Financial's ARS Pharmaceuticals position peaked at $382K in Q3 2024.
  • 187 funds tracked by Wall St. Rank held ARS Pharmaceuticals as of Q2 2025.

Based on Corebridge Financial's 13F filing for Q2 2025, filed 12 Aug 2025.